Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis

Sponsor

Peking Union Medical College Hospital (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT04892212

Collaborator

North China Pharmaceutical Group Corporation (Industry)

Enrollment

Arm

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

This a single-centre, one-arm, open-label pilot study. Eligible patients with mild proteinuric flares of lupus nephritis Class III/IV±V are received sirolimus without changing previous immunosuppressive medication during 12-week follow-up.

Primary Objective:

To investigate the efficacy of sirolimus for mild proteinuric flares in patients with Class III/IV±V lupus nephritis

Secondary Objective:

To assess the safety and tolerability of sirolimus treatment for mild proteinuric flares in patients with Class III/IV±V lupus nephritis

Condition or Disease	Intervention/Treatment	Phase
Lupus Nephritis Immunosuppression Effect of Drug	Drug: Sirolimus	Phase 2/Phase 3

Detailed Description

Lupus nephritis is a common and serious complication of systemic lupus erythematosus (SLE). It often requires aggressive immunosuppressive therapy. Although majority of patients with severe lupus nephritis achieve a complete or partial remission after 6-month induction treatment, renal flares can still occur during maintenance therapy. Whether patients with mild proteinuric flares should receive intensive immunosuppressive therapy is unclear. In pathogenesis of SLE, T-cell dysfunction is attributed to the activation of the mammalian target of rapamycin (mTOR). Previous prospective and retrospective studies in SLE or lupus nephritis showed the effect of mTOR blockade on systemic disease activity index or severe lupus nephritis as initial or maintenance therapy.

Eligible subjects with biopsy-proven Class III/IV±V lupus nephritis(ISN/RPS 2003) are received oral sirolimus without change previous immunosuppressive therapy. We follow up the included patients at Week 2, Week 4, Week6, Week 8 and Week 12 regularly.

The investigator will actively detect and inquire about the occurrence of adverse events (AEs)/ severe adverse events (SAEs) at every visit/ contact during the study. The clinical trials insurance is prepaid by sponsor to cover the design risks of the protocol and liability/ compensation to the research subject for bodily injury or death resulting from their participation in the trial.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

20 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Pilot Study of Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis

Anticipated Study Start Date :

Jun 30, 2021

Anticipated Primary Completion Date :

Jun 30, 2023

Anticipated Study Completion Date :

Oct 30, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Sirolimus group The initial dose of sirolimus is 1mg/day. And the serum trough level of sirolimus is monitored at Week 2, Week 4, Week 8, and Week 12，respectively. The target serum trough level of sirolimus is 5-8 ng/mL. The dose of sirolimus is titrated according to therapeutic drug level monitoring. The previous immunosuppressive medication is not allowed to be changed during the 3-month follow-up, unless premature discontinuation from study.	Drug: Sirolimus The daily dose of sirolimus is divided twice. Other Names: Rapamycin

Arm

Intervention/Treatment

Experimental: Sirolimus group

The initial dose of sirolimus is 1mg/day. And the serum trough level of sirolimus is monitored at Week 2, Week 4, Week 8, and Week 12，respectively. The target serum trough level of sirolimus is 5-8 ng/mL. The dose of sirolimus is titrated according to therapeutic drug level monitoring. The previous immunosuppressive medication is not allowed to be changed during the 3-month follow-up, unless premature discontinuation from study.

Drug: Sirolimus

The daily dose of sirolimus is divided twice.

Other Names:

Rapamycin

Outcome Measures

Primary Outcome Measures

The number of patients achieving sustained Renal Response(RR) [at the end of 12 weeks (3 months) from baseline]
Sustained RR is defined as satisfying all of the following criteria: 1)Proteinuria is improved by ≥50% compared with baseline 2)24-hr urine protein < 1g 3)Serum creatinine is not higher than 15% above baseline level 4)No occurrence of non-renal disease flare after achieving response to treatment.

Secondary Outcome Measures

Complete renal remission [at the end of 12 weeks (3 months) from baseline]
24-hr urine protein<0.3g/day or urine Protein-Creatinine ratio (uPCR)<300mg/g Serum creatinine not higher than 15% above baseline level
Partial renal remission [at the end of 12 weeks (3 months) from baseline]
24-hr urine protein<3.5g/day or uPCR<3500mg/g Serum creatinine not higher than 15% above baseline level
Rate of non-renal flare [during the 3-month follow up]
Central nervous system or other severe organ manifestations of SLE that necessitate aggressive immunosuppressive therapy on its own
Safety and tolerability of study medications [during the 3-month follow up]
The following parameters will be monitored: Increase of serum creatinine level>15% from baseline and whether it is reversible or irreversible Episodes with sirolimus level above the target range New-onset hypertension or worsening hypertensive control that required increase of antihypertensive medication Infectious requiring hospitalization and the causative agents Hospitalization episodes- cause, duration (days) Hypokalemia: serum potassium <3.5mmol/L Metabolic acidosis with HCO3 <17mmol/L New-onset hypercholesterolemia present at 3 months or beyond from baseline and/or addition of lipid-lowering drug(s). Premature discontinuation from the study due to treating intolerance Premature discontinuation from the study due to rapid disease progression or other reasons Failure to adhere to the protocol defined corticosteroid reduction regimen Other adverse clinical events or events considered clinically significant
Increase of serum creatinine level>15% from baseline [during the 3-month follow up]
Increase of serum creatinine level (μmol/L)>15% from baseline and whether it is reversible or irreversible.
Episodes with sirolimus level above the target range [during the 3-month follow up]
Episodes with sirolimus level above the target range（serum sirolimus trough level>8ng/mL) will be recorded.
New-onset hypertension or worsening hypertensive control that required increase of antihypertensive medication [during the 3-month follow up]
Hypertension be diagnosed when a person's systolic blood pressure (SBP) in the office or clinic is ≥140 mm Hg and/or their diastolic blood pressure (DBP) is ≥90 mm Hg following repeated examination. New-onset hypertension or worsening hypertensive control that required increase of antihypertensive medication will be recorded.
Infection requiring hospitalization [during the 3-month follow up]
Infection requiring hospitalization will be recorded including the site of infection, the causative agent and duration (days).
Hypokalemia [during the 3-month follow up]
Serum potassium <3.5mmol/L
Hypercholesterolemia [during the 3-month follow up]
New-onset hypercholesterolemia present during follow-up or beyond from baseline and/or addition of lipid-lowering drug(s)
Premature discontinuation from the study [during the 3-month follow up]
The time of of discontinuation from study will be recorded, and the discontinuation is due to: treating intolerance rapid disease progression other reasons
Failure to adhere to the protocol [during the 3-month follow up]
Failure to adhere to the protocol including: do not titer the dose of sirolimus following study protocol increase the dose of other immunosuppressives personally without the permission of physician
Changes in Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) [from baseline to end of 12 weeks]
Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) assesses disease activity by scoring 24 weighted disease activity descriptors of SLE as "present" or "absent" in preceding 10 days. A patient's total score is the sum of all marked SLE-related descriptors; a total score ranges between 0 and 105, with a higher score representing a more significant degree of disease activity. Assessment scales of SELENA-SLEDAI is available online.
Changes in Physician Global Assessement (PGA) [from baseline to end of 12 weeks]
The Physician Global Assessment (PGA) is a visual analog scale (VAS) using 3 benchmarks for assessing disease activity over the last 2 weeks. Mild flare will score 1.0 point, moderate flares will score a 2.0-2.5 point and severe flares will score a 3 on the 0-3 analog scale. PGA is available online.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 60 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Biopsy-proven Class III or IV±V lupus nephritis (ISN/RPS 2003 lupus nephritis classification) with biopsy performed within 48 weeks before inclusion.
Males or females aged 18 to 60 years old at the time of screening.
The mild proteinuric flare of lupus nephritis is defined as meeting all of the following criteria :

Persistently increased proteinuria after complete remission, and 24-hr proteinuria≥1.0g/day or doubling of proteinuria after partial remission, and 24-hr proteinuria≥2.0g/day
No hypoalbuminemia: serum albumin ≥35g/L
Stable renal function: serum creatinine<25% increase above the level at the time of renal disease remission

Eligible to sign informed-consent independently

Exclusion Criteria:

Renal disease unrelated to SLE (e.g. diabetes mellitus, other glomerular or tubulointerstitial diseases, renovascular disease), or transplanted kidney
Estimate glomerular filtration rate (eGFR by CKD-EPI)<45mL/min per 1.73m^2 at the time of screening
Renal biopsy showing cellular of fibrocellular crescent in more than 25% of glomeruli
Central nervous system (CNS) or other severe organ manifestations of lupus that necessitate aggressive immunosuppressive therapy on its own.
Co-morbidities that require corticosteroid therapy (e.g. asthma, inflammatory bowel disease)
Any increased dose of corticosteroids or other immunosuppressive medication including cyclophosphamide, mycophenolate, leflunomide, calcineurin inhibitors, azathioprine, methotrexate, or use of biological agents regardless of duration, with the past six months
Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection history: seropositivity of HBV surface antigen (HBsAg) or HCV antibodies (HCV-Ab)
Women who are pregnant or breastfeeding
Women with childbearing potential or their male partners, who refuse to use an effective birth control method